Positive News SentimentPositive NewsNASDAQ:VIGL Vigil Neuroscience (VIGL) Stock Price, News & Analysis $3.99 +0.13 (+3.37%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Vigil Neuroscience Stock (NASDAQ:VIGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vigil Neuroscience alerts:Sign Up Key Stats Today's Range$3.80▼$4.1250-Day Range$2.92▼$3.9952-Week Range$2.47▼$9.24Volume94,876 shsAverage Volume251,883 shsMarket Capitalization$158.20 millionP/E RatioN/ADividend YieldN/APrice Target$16.60Consensus RatingModerate Buy Company OverviewVigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.Read More… $5k to $1.3m in just 3 trades (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. Vigil Neuroscience Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks69th Percentile Overall ScoreVIGL MarketRank™: Vigil Neuroscience scored higher than 69% of companies evaluated by MarketBeat, and ranked 358th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingVigil Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVigil Neuroscience has only been the subject of 2 research reports in the past 90 days.Read more about Vigil Neuroscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.15) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vigil Neuroscience is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vigil Neuroscience is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVigil Neuroscience has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vigil Neuroscience's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.61% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vigil Neuroscience has recently decreased by 3.66%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVigil Neuroscience does not currently pay a dividend.Dividend GrowthVigil Neuroscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.61% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vigil Neuroscience has recently decreased by 3.66%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News SentimentN/A News SentimentVigil Neuroscience has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders33.03% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vigil Neuroscience's insider trading history. Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIGL Stock News HeadlinesSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)October 9, 2024 | prnewswire.comBuy Rating Affirmed for Vigil Neuroscience Inc Amid Promising Alzheimer’s Treatment PotentialOctober 9, 2024 | markets.businessinsider.com$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…October 17, 2024 | WealthPress (Ad)FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trialSeptember 20, 2024 | msn.comBuy Rating Affirmed for Vigil Neuroscience Inc. as FDA Lifts Clinical Hold and Phase 1 Trials Show PromiseSeptember 18, 2024 | markets.businessinsider.comVigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment TrialSeptember 17, 2024 | marketwatch.comVigil says FDA removed partial hold on Alzheimer’s candidateSeptember 17, 2024 | msn.comVigil Neuroscience, Inc.: Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927September 17, 2024 | finanznachrichten.deSee More Headlines VIGL Stock Analysis - Frequently Asked Questions How have VIGL shares performed this year? Vigil Neuroscience's stock was trading at $3.38 at the beginning of 2024. Since then, VIGL shares have increased by 18.0% and is now trading at $3.99. View the best growth stocks for 2024 here. How were Vigil Neuroscience's earnings last quarter? Vigil Neuroscience, Inc. (NASDAQ:VIGL) released its earnings results on Tuesday, August, 13th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.02. When did Vigil Neuroscience IPO? Vigil Neuroscience (VIGL) raised $112 million in an initial public offering on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share. How do I buy shares of Vigil Neuroscience? Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vigil Neuroscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vigil Neuroscience investors own include NVIDIA (NVDA), Meta Platforms (META), Exxon Mobil (XOM), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Home Depot (HD). Company Calendar Last Earnings8/13/2024Today10/17/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIGL CUSIPN/A CIK1827087 Webvigilneuro.com Phone857-254-4445FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Stock Price Target$16.60 High Stock Price Target$23.00 Low Stock Price Target$4.00 Potential Upside/Downside+316.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.02% Return on Assets-62.85% Debt Debt-to-Equity RatioN/A Current Ratio8.39 Quick Ratio8.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book1.23Miscellaneous Outstanding Shares39,650,000Free Float26,552,000Market Cap$158.20 million OptionableNot Optionable Beta1.95 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:VIGL) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.